NEW YORK (GenomeWeb News) – DxTerity Diagnostics last night said that the City of Hope research center will use the firm’s Non-Enzymatic Amplification Technology, or NEAT, genomics testing platform in a program to develop antisense therapeutics.
DxTerity’s platform enables gene-controlled ligation of oligonucleotide probes inside of cells, the Rancho Dominguez, Calif.-based firm said. In addition to applying the technology to therapeutics development, the platform enables the development of “simple and affordable nucleic acid-based tests,” said DxTerity.
City of Hope researchers believe the technology could potentially help develop a new class of therapeutics with reduced side effects.
Terms of the agreement were not disclosed.